semaglutide fda shortage status january 2025 Federal judge upholds FDA's removal of Ozempic, Wegovy from drug list GLP-1 No Longer on FDA's – FDA Ends Semaglutide Shortage Listing,

Clinical studies show it can reduce the risk of major cardiovascular events such as heart attacks and strokes, and slow kidney damage in people with type 2 diabetes

The practical recommendation is to adjust expectations: count standard drinks carefully (your previous tolerance may not apply), eat before drinking, allow extra time for alcohol to clear, and avoid alcohol during dose escalation when GI side effects are most active

Personal Risk Retatrutide injection site reactions are rare but may occur in anyone using this drug

Elevated blood homocysteine and risk of Alzheimer's dementia: an updated systematic review and meta-analysis based on prospective studies

This approach can enhance appetite management, energy levels, and overall diet